PMC:7536913 / 10473-11498
Annnotations
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T29 | 134-181 | Disease | denotes | severe acute respiratory syndrome coronavirus 2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T30 | 134-167 | Disease | denotes | severe acute respiratory syndrome | http://purl.obolibrary.org/obo/MONDO_0005091 |
T31 | 183-187 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T54 | 102-105 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T55 | 409-410 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T56 | 547-549 | http://purl.obolibrary.org/obo/CLO_0008935 | denotes | S9 |
T57 | 814-815 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T58 | 924-931 | http://purl.obolibrary.org/obo/NCBITaxon_33208 | denotes | animals |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T7 | 23-27 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T8 | 943-947 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
92 | 134-181 | Species | denotes | severe acute respiratory syndrome coronavirus 2 | Tax:2697049 |
93 | 315-323 | Species | denotes | patients | Tax:9606 |
94 | 1009-1017 | Species | denotes | patients | Tax:9606 |
95 | 183-192 | Species | denotes | SARS‐CoV2 | Tax:2697049 |
96 | 543-546 | Disease | denotes | ICH | MESH:D002543 |
97 | 846-849 | Disease | denotes | ICH | MESH:D002543 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T5 | 670-678 | Phenotype | denotes | oncology | http://purl.obolibrary.org/obo/HP_0002664 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T70 | 0-324 | Sentence | denotes | The global support for drug and vaccine development, including streamlining nonclinical requirements, has allowed candidates, such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV2) antibodies, to move quickly into the clinic to most efficiently determine if the experimental treatment is effective for patients. |
T71 | 325-542 | Sentence | denotes | The practice of deferring or eliminating certain preclinical studies while there is a degree of uncertainty in the experimental candidate for specific life‐threatening illnesses with no effective treatment is not new. |
T72 | 543-691 | Sentence | denotes | ICH S9 Guideline “Nonclinical Evaluation for Anticancer Pharmaceuticals” provides for such regulatory flexibility for advanced oncology indications. |
T73 | 692-850 | Sentence | denotes | We encourage regulators to apply this approach to other life‐threatening illnesses across therapeutic areas, and to model a global harmonized approach as ICH. |
T74 | 851-1025 | Sentence | denotes | The benefits to society could be significant—by reducing the need to use animals, modernize drug development, and potentially make new therapies available to patients faster. |